Bleeding diathesis

CHOP's Hemostasis and Thrombosis Center Celebrates 50th Anniversary

Retrieved on: 
Wednesday, June 7, 2023
Ruth M. Rothstein CORE Center, Bleeding, Vein, CHOP, HIV, Hematology, Mother, Disability, Emicizumab, Hockey, Therapy, Novel, Not, Haemophilia, IX, Philadelphia, Coagulopathy, DSM-IV codes, Bleeding diathesis, Child, HTC, CDC, Pain, Social, Disorder, AIDS, MD, Patient, Nursing, Division, Maternal and Child Health Bureau, Thrombosis, Diagnosis, Hospital, World Blood Donor Day, Caregiver, FDA, Hemostasis, Football, National Intrepid Center of Excellence, Disease, Children's Hospital of Philadelphia, Birth control, Pharmaceutical industry

PHILADELPHIA, June 7, 2023 /PRNewswire/ -- The Hemostasis and Thrombosis Center (HTC) at Children's Hospital of Philadelphia (CHOP) is proudly celebrating 50 years of providing comprehensive care to children and adolescents with hemophilia and other inherited bleeding or clotting disorders. The Center was founded in 1973 and was one of the first HTCs established in the country and is considered a Center of Excellence for the diagnosis, treatment and prevention of bleeding and clotting disorders, serving as a national resource for other institutions.

Key Points: 
  • PHILADELPHIA, June 7, 2023 /PRNewswire/ -- The Hemostasis and Thrombosis Center (HTC) at Children's Hospital of Philadelphia (CHOP) is proudly celebrating 50 years of providing comprehensive care to children and adolescents with hemophilia and other inherited bleeding or clotting disorders.
  • "What started at CHOP as caring for 48 patients a year with hemophilia has grown into providing care for over 1,000 children with all types of bleeding and clotting disorders at our Center," says Leslie Raffini, MD, Director of the Hemostasis and Thrombosis Center at Children's Hospital of Philadelphia.
  • Hemophilia is an X-linked inherited bleeding disorder that is caused by a clotting factor deficiency that can cause frequent, painful joint bleeds and disability.
  • During this time, donated blood was the only treatment available for hemophilia patients, which led to many of them becoming infected with HIV.

Medicure Announces that the Shortened AGGRASTAT® Versus INTEGRILIN® in Percutaneous Coronary Intervention (SAVI-PCI) Study has Met its Primary Endpoint

Retrieved on: 
Thursday, November 4, 2021
Bleeding diathesis, TCT, Comment, Industry, Medical College of Wisconsin, Medical college, NSTE-ACS, Platelet, Temperature, Trauma, OTC, Risk, Legislation, Hypersensitivity, Anticoagulant, Research, Injection, Forward-looking statement, PCI, GP, Annual general meeting, TSX Venture Exchange, Thrombocytopenia, Tablet, Marketing, Bleeding, Patient, Eptifibatide, Myocardial infarction, Division, Bob Marley, CEO, Doctor of Philosophy, Cardiology, U.S. Securities and Exchange Commission, PPM, Creatinine, Manuscript, Pharmacy, Government, Perception, SAVI, Company, MB, Death, Cardiac catheterization, Health status of Asian Americans, Pharmaceutical industry, Risk management, Medical device, Birth control

A third arm of bolus plus long (12 18 hour) infusion AGGRASTAT was later added to the study.

Key Points: 
  • A third arm of bolus plus long (12 18 hour) infusion AGGRASTAT was later added to the study.
  • The primary endpoint was driven by the occurrence of PPM, defined as a troponin value 3 times the upper limit of normal when compared to baseline.
  • There was only a single death in the study (INTEGRILIN arm) and 2 uTVR events (1 in each of the short and long AGGRASTAT arms, respectively).
  • "We are very pleased to announce that the SAVI-PCI study met its primary endpoint, demonstrating the non-inferiority of a bolus plus short-infusion of AGGRASTAT when compared to longer infusion regimens.